Efficacy of Low-Dose Rituximab in Primary Immune Thrombocytopenia

Objective: To explore the effect of low-dose rituximab in primary immune thrombocytopenia. Methods: From January 2022 to January 2023, 60 patients with primary immune thrombocytopenia were randomly divided into two groups. The control group was treated with standard doses of rituximab, and the observation group was treated with low doses of rituximab. Rituximab was used for treatment, and the clinical curative effect of the two groups was observed. Results: Before treatment, there was no statistically significant difference in platelet count (PLT), anti-GPⅡb/Ⅲa antibody, and anti-GPⅠb/Ⅸ antibody between the two groups (P > 0.05). After treatment, the PLT of the two groups increased significantly. Antibodies were all decreased, and there was no significant difference between the two groups (P > 0.05). The incidence of adverse reactions in the observation group was 13.33%, and that in the control group was 40.00%. The adverse reactions in the observation group were significantly lower than the control group (P < 0.05). Conclusion: In the clinical treatment of primary immune thrombocytopenia, low-dose rituximab can control the progression of the disease, improve blood routine indicators, and have fewer adverse reactions.